preval
asthma
vari
countri
countri
isaac
worldwid
questionnairebas
multicentr
studi
preval
asthma
allerg
rhiniti
atop
dermat
children
age
year
centr
countri
countri
highest
preval
asthma
symptom
uk
australia
new
zealand
republ
ireland
follow
north
central
south
america
lowest
preval
found
eastern
europ
indonesia
greec
china
taiwan
uzbekistan
india
ethiopia
differ
report
centr
highest
lowest
rate
variat
centil
gener
asthma
common
industrialis
nation
western
lifestyl
von
mutiu
studi
role
cultur
environment
differ
diseas
preval
east
west
germani
follow
reunif
children
live
east
germani
lower
preval
asthma
hayfev
despit
expos
higher
level
atmospher
pollut
higher
rate
bronchiti
mid
preval
hayfev
atop
sensitis
increas
whilst
preval
asthma
remain
reason
differ
clear
possibl
factor
aetiolog
asthma
includ
ethnic
origin
childhood
respiratori
diseas
allergen
exposur
diet
socioeconom
differ
suggest
improv
hygien
western
world
result
differ
exposur
infecti
diseas
one
consequ
increas
tendenc
atop
respons
environment
recent
epidem
atop
diseas
asthma
may
occur
consequ
declin
certain
childhood
infect
gener
lack
exposur
broad
rang
infecti
agent
first
year
life
idea
support
studi
children
environ
would
expect
lead
increas
viral
infect
ball
et
investig
children
part
tucson
children
respiratori
studi
children
older
sibl
home
attend
day
care
therefor
like
expos
respiratori
viru
infect
like
frequent
wheez
episod
preced
year
age
year
less
like
frequent
wheez
age
year
fig
children
reduc
risk
atop
sensitis
asthma
school
member
multicentr
allergi
studi
ma
group
shown
german
children
repeat
upper
respiratori
tract
infect
infect
nonrespiratori
virus
herp
simplex
infanc
may
reduc
risk
asthma
develop
school
age
measl
infect
appear
inhibit
atop
diseas
amongst
children
guineabissau
shaheen
et
al
shown
recov
natur
measl
infect
half
incid
atopi
posit
respons
hous
dust
compar
children
studi
scottish
schoolchildren
bodner
et
also
shown
reduct
atop
diseas
case
allerg
rhiniti
children
histori
measl
contrast
studi
paunio
et
finland
found
posit
associ
measl
infect
atopi
children
establish
atop
diseas
may
demonstr
remiss
diseas
measl
infect
recurr
symptom
follow
recoveri
matricardi
et
shown
respiratori
allergi
italian
air
forc
cadet
less
frequent
heavi
exposur
orofaec
foodborn
microb
demonstr
posit
serolog
toxoplasma
gondii
helicobact
pylori
hepat
westernis
semisteril
diet
may
facilit
atopi
influenc
overal
pattern
commens
pathogen
stimul
gutassoci
lymphoid
tissu
number
addit
possibl
nonvir
protect
infecti
influenc
includ
prenat
perinat
bacteri
infect
exposur
differ
intestin
microflora
children
farmer
rural
area
lower
preval
symptom
allerg
rhiniti
allergen
specif
ige
nonfarm
children
tuberculin
test
evid
natur
exposur
tuberculosi
fewer
symptom
asthma
eczema
shown
treatment
oral
antibiot
age
year
associ
subsequ
atop
diseas
mechan
effect
unclear
may
antibiot
associ
disrupt
normal
bowel
flora
necessari
matur
immun
system
altern
elimin
pathogen
antibiot
therapi
may
limit
benefici
effect
matur
immun
system
infect
suggest
exposur
virus
infecti
agent
earli
life
protect
develop
atopi
asthma
cours
infect
associ
signific
morbid
mortal
dramat
reduc
prevent
strategi
improv
public
health
measl
vaccin
possibl
infect
help
immun
system
matur
earli
predominantli
toward
state
absenc
individu
predispos
genet
addit
environment
factor
allergen
exposur
matern
cigarett
smoke
fail
happen
consequ
atop
diseas
includ
asthma
characteris
inflamm
phenotyp
use
immunomodulatori
inhibit
cell
function
may
help
deviat
immun
system
away
state
atop
diseas
asthma
like
develop
strategi
would
requir
identif
individu
high
risk
treatment
earli
life
signific
ethic
problem
human
trial
drug
infant
young
children
possibl
harm
effect
immun
deviat
unknown
spite
possibl
protect
influenc
wide
rang
infecti
agent
includ
respiratori
virus
subsequ
develop
atopi
asthma
infect
respiratori
virus
common
caus
wheez
episod
infanc
discuss
exacerb
asthmat
children
wheez
episod
first
year
associ
viral
respiratori
respiratori
syncyti
viru
rsv
rhinoviru
influenza
b
frequent
children
rsv
caus
bronchiol
potenti
seriou
lower
respiratori
tract
ill
signific
mortal
respiratori
virus
rsv
often
associ
subsequ
asthma
sigur
et
al
report
infant
suffer
wheez
rsv
infect
requir
hospitalis
like
prospect
identifi
control
subject
allergenspecif
ige
asthma
age
studi
fail
demonstr
relationship
rsv
infect
martinez
studi
relationship
childhood
respiratori
disord
prognosi
develop
asthma
tucson
children
respiratori
studi
total
newborn
babi
recruit
studi
first
year
life
children
suffer
wheez
earli
life
age
year
could
divid
two
group
persist
wheezer
still
episod
wheez
age
year
higher
level
ige
higher
preval
atop
dermat
higher
preval
matern
asthma
transient
wheezer
without
wheez
age
year
like
small
airway
impair
lung
function
birth
rather
factor
associ
atopi
differ
observ
two
group
respons
time
first
infect
wheez
episod
occur
around
year
due
rsv
twothird
episod
persist
wheezer
show
increas
serum
ige
seen
transient
wheezer
eosinopenia
observ
transient
wheezer
children
lower
respiratori
tract
ill
without
wheez
eosinophil
count
maintain
persist
wheezer
episod
also
observ
sever
persist
wheezer
suggest
persist
wheezer
therefor
overrepres
studi
children
hospitalis
rsv
infect
may
explain
studi
show
strong
associ
subsequ
examin
relationship
lower
respiratori
tract
ill
age
year
preval
childhood
atopi
wheez
tuscon
cohort
children
lower
respiratori
tract
infect
due
rsv
increas
risk
wheez
first
year
increas
risk
disappear
age
year
similar
increas
risk
observ
pathogen
inde
lower
respiratori
tract
infect
neg
test
studi
may
indic
rhinoviru
infect
sinc
sensit
method
detect
includ
associ
found
infect
rsv
pathogen
subsequ
develop
atopi
whether
respiratori
virus
actual
caus
subsequ
asthma
unclear
infant
young
children
wheez
acut
respiratori
viru
infect
appear
risk
wheez
later
childhood
may
children
factor
small
airway
defici
type
immun
predispos
wheez
viru
infect
earli
late
childhood
may
also
predispos
develop
subsequ
asthma
shown
low
respons
significantli
lower
ratio
pbmc
children
hospitalis
rsv
rel
pbmc
control
children
respiratori
virus
may
simpli
identifi
predispos
children
infanc
sinc
respond
infect
wheez
may
may
influenc
develop
asthma
progress
asthmat
airway
diseas
link
respiratori
infect
asthma
exacerb
well
establish
although
incomplet
understood
associ
attribut
bacteri
clear
major
exacerb
due
viral
rather
bacteri
infect
virus
implic
caus
primarili
respiratori
diseas
includ
influenza
parainfluenza
enterovirus
adenoviru
respiratori
syncyti
viru
rsv
rhinoviru
coronaviru
virus
first
isol
influenza
earli
like
addit
virus
exist
yet
identifi
recent
studi
children
netherland
identifi
new
human
caus
symptom
similar
rsv
rang
upper
respiratori
tract
diseas
sever
bronchiol
pneumonia
serolog
demonstr
human
metapneumoviru
circul
human
least
year
virtual
children
netherland
expos
viru
viral
respiratori
tract
infect
major
caus
wheez
infant
children
role
may
underestim
earli
epidemiolog
studi
difficulti
isol
studi
carri
limit
viral
cultur
serolog
alway
includ
sensit
method
detect
rhinovirus
coronavirus
introduct
molecular
biolog
techniqu
rtpcr
studi
implic
viral
infect
major
asthma
exacerb
apart
method
detect
use
studi
design
also
influenc
frequenc
detect
respiratori
virus
asthma
exacerb
often
occur
follow
preced
histori
common
cold
symptom
clinic
sampl
delay
child
brought
gp
accid
emerg
depart
sampl
taken
time
viru
shed
fall
isol
becom
difficult
earli
studi
found
specimen
obtain
first
day
ill
posit
fell
specimen
taken
first
highest
rate
viru
detect
found
prospect
studi
children
follow
close
sampl
taken
soon
symptom
commenc
indirect
evid
popul
studi
establish
signific
correl
season
variat
wheez
episod
young
children
peak
viru
studi
schoolchildren
southampton
uk
specimen
obtain
respiratori
infect
drop
peak
expiratori
flow
rate
season
pattern
identif
respiratori
virus
cohort
associ
peak
local
hospit
admiss
children
asthma
indic
role
infect
sever
asthma
direct
evid
implic
viral
infect
asthma
exacerb
provid
studi
show
increas
rate
viru
detect
individu
suffer
asthma
attack
studi
fall
two
main
type
crosssect
prospect
virus
identifi
asthma
exacerb
children
highest
rate
identif
studi
subject
follow
prospect
allow
collect
clinic
specimen
earli
cours
ill
pcrbase
method
diagnosi
use
addit
serolog
cultur
methodolog
use
allow
detect
rhinovirus
children
age
year
identifi
questionnair
suffer
symptom
asthma
children
follow
prospect
period
month
diari
card
peak
flow
monitor
use
identifi
episod
fall
peak
flow
upper
respiratori
symptom
cough
wheez
nasal
sampl
taken
earli
episod
combin
cultur
rtpcr
detect
virus
episod
frequent
rhinoviru
rake
et
recent
report
result
crosssect
studi
infant
children
sever
wheez
attend
emerg
depart
virginia
usa
studi
use
rtpcr
viral
cultur
detect
rang
virus
includ
rhinoviru
rsv
coronaviru
enteroviru
influenza
adenoviru
nasal
wash
sampl
respiratori
virus
detect
wheez
infant
age
year
older
wheez
children
predomin
pathogen
rsv
infant
rhinoviru
older
children
age
year
wheez
frequent
posit
rtpcr
rhinoviru
togeth
posit
serum
rast
aeroallergen
nasal
eosinophilia
elev
nasal
ecp
freymuth
et
similarli
use
mixtur
convent
molecular
method
detect
rhinoviru
enteroviru
rsv
adenoviru
coronaviru
influenza
parainfluenza
chlamydia
pneumonia
mycoplasma
pneumonia
nasal
aspir
infant
children
hospitalis
sever
attack
asthma
overal
pathogen
detect
studi
frequent
identifi
rhinoviru
rsv
use
rtpcr
studi
increas
detect
rate
rhinoviru
rsv
respect
rate
detect
virus
exacerb
individu
asymptomat
order
contrast
studi
transtrach
aspir
adult
asthmat
yield
spars
bacteri
cultur
correl
clinic
ill
differ
normal
subject
almost
studi
asthmat
predomin
virus
rhinovirus
rsv
parainfluenza
virus
rhinovirus
alon
detect
around
virusinduc
asthma
attack
adenovirus
enterovirus
coronavirus
also
detect
less
frequent
influenza
found
annual
epidem
child
asthma
develop
infect
rhinoviru
coronaviru
rsv
cultur
likelihood
associ
asthma
attack
around
prospect
complex
area
review
number
consid
briefli
yet
knowledg
remain
incomplet
much
data
concern
mechan
virusinduc
wheez
asthma
deriv
experiment
viru
infect
mild
adult
asthmat
usual
specif
serotyp
rhinoviru
vitro
work
viru
infect
epitheli
cell
cultur
system
anim
studi
data
may
may
relev
virusinduc
wheez
infant
children
wherea
respiratori
virus
influenza
parainfluenza
rsv
adenoviru
well
recognis
caus
lower
airway
syndrom
pneumonia
bronchiol
capabl
replic
lower
airway
uncertainti
whether
rhinoviru
infect
occur
lower
airway
well
upper
respiratori
tract
although
possibl
nasopharyng
contamin
rule
rhinoviru
detect
lower
airway
clinic
specimen
tracheal
rtpcr
cultur
rhinoviru
cultur
cell
line
bronchial
epitheli
cell
replic
demonstr
primari
cultur
bronchial
epitheli
final
use
situ
hybridis
demonstr
rhinoviru
bronchial
biopsi
subject
follow
experiment
data
confirm
rhinoviru
infect
lower
airway
occur
directli
implic
lower
airway
infect
pathogenesi
asthma
exacerb
interact
respiratori
viru
infect
chronic
asthmat
airway
inflamm
result
respiratori
symptom
sever
suffer
nonasthmat
individu
detail
immunolog
mechan
underli
interact
current
unclear
diseas
syndrom
follow
infect
viru
consequ
direct
harm
effect
viru
immunopatholog
result
host
immun
respons
may
unavoid
viru
elimin
asthmat
individu
exacerb
may
occur
function
interact
viral
patholog
asthmat
patholog
ie
differ
mechan
end
effect
function
share
pathogenet
mechan
addit
even
synergist
fashion
preexist
asthmat
inflamm
might
interfer
effect
antivir
respons
thu
allow
viru
caus
increas
airway
damag
altern
viru
infect
might
increas
sensit
asthmat
airway
trigger
factor
allergen
exposur
fact
like
virusinduc
asthma
exacerb
occur
combin
four
type
interact
viral
infect
epitheli
cell
import
compon
antivir
immun
respons
produc
cytokin
chemokin
rant
capabl
activ
recruit
varieti
cell
includ
lymphocyt
eosinophil
neutrophil
effici
clearanc
viru
orchestr
antibodi
tcell
produc
type
cytokin
asthmat
airway
rich
type
cytokin
may
result
virusspecif
cell
type
mix
type
charact
case
viru
infect
could
follow
ineffici
antivir
immun
respons
delay
viral
clearanc
amplif
ongo
asthmat
inflamm
consequ
interact
sever
often
prolong
viral
ill
exacerb
asthma
success
vaccin
prevent
respiratori
viru
infect
limit
signific
variat
within
major
viru
type
caus
diseas
serotyp
rhinoviru
effect
vaccin
introduc
influenza
virus
display
antigen
shift
drift
new
vaccin
must
develop
everi
year
cover
strain
preval
time
new
pandem
strain
aris
delay
suffici
quantiti
vaccin
made
avail
vaccin
rsv
experienc
major
setback
use
formalin
inactiv
viru
young
babi
result
increas
diseas
sever
follow
subsequ
viru
vaccin
children
requir
hospitalis
subsequ
infect
rsv
compar
control
lung
two
vaccin
children
die
contain
eosinophil
infiltr
suggest
formalin
inactiv
may
modifi
epitop
within
rsv
g
f
surfac
glycoprotein
result
modifi
immun
respons
subsequ
infect
enhanc
vaccin
individu
demonstr
number
differ
individu
suffer
natur
rsv
infect
includ
lack
specif
mucos
antibodi
defici
neutralis
fusioninhibit
serum
also
differ
cellmedi
immun
respons
vaccin
individu
demonstr
peripher
eosinophilia
exagger
lymphocyt
prolif
respons
protect
rsv
infect
success
vaccin
would
need
provid
effect
protect
natur
infect
frequent
follow
would
administ
earli
infanc
effect
infant
bronchiol
two
main
approach
therapi
viral
exacerb
first
use
antivir
agent
direct
action
viru
larg
number
virus
produc
similar
clinic
syndrom
use
specif
antivir
drug
requir
rapid
accur
diagnost
method
pcr
altern
approach
treat
virusinduc
inflamm
perhap
strategi
promot
type
respons
individu
excess
type
respons
understand
complex
antivir
immun
respons
particular
may
alter
context
preexist
chronic
airway
diseas
asthma
essenti
first
step
work
need
elucid
import
site
interact
immunolog
network
asthma
viru
infect
greater
knowledg
requir
identifi
key
target
therapeut
intervent
aim
minimis
immunopatholog
whilst
maintain
enhanc
host
antivir
immun
respons
current
much
treatment
infect
exacerb
asthma
symptomat
consist
increas
bronchodil
support
form
oxygen
sever
case
noninvas
invas
ventilatori
measur
corticosteroid
wide
use
inhal
oral
form
antiinflammatori
action
major
role
asthma
effect
corticosteroid
result
action
mani
point
variou
inflammatori
whilst
undoubtedli
contribut
benefici
effect
also
result
signific
sideeffect
particular
system
steroid
treatment
prolong
frequent
addit
system
steroid
may
interfer
antivir
immun
respons
result
reduc
viral
specif
antivir
agent
exist
influenza
virus
includ
amantidin
rimantidin
recent
develop
neuraminidas
inhibitor
zanamivir
oseltamivir
use
current
restrict
adult
influenza
rel
unusu
caus
asthma
exacerb
children
especi
outsid
epidem
ribavirin
nucleosid
analogu
activ
rsv
vivo
also
influenza
vitro
nebulis
ribavirin
therapi
licens
use
hospitalis
infant
children
first
day
rsv
bronchiol
howev
expens
unproven
benefit
clinic
outcom
rsvenrich
immunoglobulin
effect
prophylaxi
infant
high
risk
rsv
trial
rsv
neutralis
monoclon
antibodi
progress
rhinovirus
major
target
drug
treatment
estim
rhinovirus
result
cold
per
year
young
children
yet
effect
agent
avail
clinic
use
capsid
bindingcanyon
inhibitor
block
bind
rhinovirus
host
cell
receptor
case
major
group
one
exampl
phase
clinic
trial
pleconaril
picovir
drug
extrem
potent
clinic
use
often
limit
serotyp
specif
rapid
develop
resist
altern
target
includ
solubl
inhibit
major
rhinoviru
infect
vitro
conserv
viral
enzym
protein
rnadepend
rna
transcriptas
protein
associ
atphelicas
cystein
proteas
role
infect
aetiolog
asthma
complex
current
evid
suggest
overal
load
infecti
agent
includ
respiratori
virus
encount
earli
life
import
factor
influenc
matur
immun
system
type
bia
birth
toward
predominantli
type
respons
thu
avoid
atop
diseas
hygien
hypothesi
rel
steril
environ
present
industrialis
western
countri
therefor
contribut
recent
epidem
asthma
atopi
whether
specif
infect
greater
lesser
protect
valu
unclear
import
question
strategi
deriv
mimic
benefici
effect
childhood
infect
whilst
avoid
morbid
potenti
mortal
natur
convinc
evid
specif
infect
caus
atopi
asthma
howev
strong
associ
sever
wheez
episod
infanc
commonli
due
viru
infect
particular
rsv
subsequ
wheez
asthma
later
life
particularli
children
featur
atopi
infect
respiratori
virus
common
trigger
wheez
infant
exacerb
asthma
older
children
virus
detect
episod
rhinoviru
common
age
group
rsv
import
infant
young
children
knowledg
immunopathogenet
mechan
involv
remain
incomplet
current
therapi
virusinduc
exacerb
asthma
reli
increas
treatment
preexist
diseas
corticosteroid
form
major
antiinflammatori
compon
therapi
use
associ
signific
sideeffect
especi
use
system
high
dose
antivir
agent
exist
particular
influenza
virus
effect
use
drug
asthma
requir
viral
diagnosi
commenc
treatment
earli
cours
exacerb
target
highrisk
group
prophylaxi
clinic
effect
broad
spectrum
agent
yet
avail
rhinovirus
commonest
caus
exacerb
altern
strategi
drug
develop
may
involv
identif
key
factor
common
exacerb
induc
rang
differ
virus
increas
knowledg
interact
requir
design
treatment
increas
viru
clearanc
minimis
immunopatholog
